ReviewInternational journal of molecular sciences2026
Research Advances and Biological Features of IgA for Immune-Related Diseases.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the predominant antibody isotype at human mucosal surfaces, immunoglobulin A (IgA) exerts critical functions in mucosal defense and systemic immune homeostasis. The two IgA subclasses, IgA1 and IgA2, possess distinct structural and functional features and assemble into dimeric IgA (dIgA) and secretory IgA (sIgA) under physiological conditions. With advances in cryo-electron microscopy, the molecular architecture and assembly of sIgA have been clearly characterized. While IgA protects hosts from pathogenic infection and sustains immune balance, aberrantly altered IgA contributes to the pathogenesis of IgA nephropathy and autoimmune encephalitis. To date, IgA-based therapeutics have displayed promising therapeutic efficacy against respiratory disorders, inflammatory bowel diseases and oral fungal infections. Through standardized retrieval and categorical sorting of the published literature covering IgA structure, physiological functions, disease pathogenic mechanisms and therapeutic research, this review systematically organizes relevant research advances, analyzes the bottlenecks and translational prospects of IgA-targeted therapeutics, and provides objective references to accelerate the clinical translation of IgA antibody agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.